pramlintide acetate · Astrazeneca Ab · NDA 021332
Symlin
Earliest generic entry, as listed · earliest of 2 marketed strengths
Open now
No marketed reference-listed strength; date taken from all listed strengths.
No unexpired patents or exclusivities are listed for this product.
Listed patents · 0 unexpired
No unexpired patents listed.
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 3
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 021332 · 001 · discontinued | injectable, subcutaneous | EQ 3MG BASE/5ML (EQ 600MCG BASE/ML) | open |
| 021332 · 002 · RLD · discontinued | injectable, subcutaneous | EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML) | open |
| 021332 · 003 · RLD · discontinued | injectable, subcutaneous | EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML) | open |